Analyst Expectations For Bristol-Myers Squibb's Future

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Bristol-Myers Squibb BMY in the last three months.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $60.77, a high estimate of $84.00, and a low estimate of $50.00. A 6.82% drop is evident in the current average compared to the previous average price target of $65.22.

Breaking Down Analyst Ratings: A Detailed Examination

The analysis of recent analyst actions sheds light on the perception of Bristol-Myers Squibb by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bristol-Myers Squibb. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bristol-Myers Squibb compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Bristol-Myers Squibb's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Bristol-Myers Squibb's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Bristol-Myers Squibb analyst ratings.

All You Need to Know About Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Key Indicators: Bristol-Myers Squibb's Financial Health

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Negative Revenue Trend: Examining Bristol-Myers Squibb's financials over 3 months reveals challenges. As of 30 September, 2023, the company experienced a decline of approximately -2.25% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Bristol-Myers Squibb's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.58% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Bristol-Myers Squibb's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.32%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Bristol-Myers Squibb's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.09%, the company showcases efficient use of assets and strong financial health.

Debt Management: Bristol-Myers Squibb's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.35, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

Analyst Ratings: What Are They?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.